Norris Financial Group’s ImmunityBio IBRX Stock Holding History

Norris Financial Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$124K	Hold	14,126	–	–	0.05%	80
2026 Q1	$108K	Hold	14,126	–	–	0.04%	97
2025 Q4	$28K	Hold	14,126	–	–	0.01%	97
2025 Q3	$34.8K	Hold	14,126	–	–	0.01%	98
2025 Q2	$37.3K	Hold	14,126	–	–	0.02%	82
2025 Q1	$42.5K	Hold	14,126	–	–	0.02%	85
2024 Q4	$36.2K	Hold	14,126	–	–	0.02%	81
2024 Q3	$52.5K	Buy	14,126 +376	+3%	+$1.74K	0.03%	75
2024 Q2	$86.9K	Buy	13,750 +2,750	+25%	+$18.1K	0.05%	77
2024 Q1	$59.1K	Hold	11,000	–	–	0.03%	74
2023 Q4	$55.2K	Hold	11,000	–	–	0.03%	67
2023 Q3	$18.6K	Hold	11,000	–	–	0.01%	63
2023 Q2	$30.6K	Sell	11,000 -1,000	-8%	-$2.83K	0.02%	63
2023 Q1	$21.8K	Buy	+12,000	New	+$37.3K	0.02%	65

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norris Financial Group's IBRX Position: Q2 2026 in Review

Norris Financial Group held its ImmunityBio (IBRX) position steady in Q2 2026 at 14,126 shares worth $124K. The position accounts for 0.05% of the portfolio, ranked #80.

Norris Financial Group first reported a position in IBRX in Q1 2023 and has held it in 14 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Norris Financial Group held 14,126 shares of ImmunityBio worth $124K as of Q2 2026.
Norris Financial Group left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up 0.05% of Norris Financial Group's portfolio in Q2 2026, its #80 holding.
Norris Financial Group first reported a position in ImmunityBio in Q1 2023 and has held it in 14 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Norris Financial Group's 13F filing for Q2 2026, filed 5 Aug 2026.